

Applicant : Murphy, et al.
Serial No. : 09/886,400
Filed : June 20, 2001
Page : 2 of 15

Attorney's Docket No.: 56446-20003.20/-004005/
D1120-4

Amendment to the Claims:

Please amend the claims as follows:

Please cancel claims 96 to 98 and 133 to 137, without prejudice.

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

Claim 1 to 92 (canceled)

Claim 93 (currently amended): An isolated or recombinant polypeptide having at least 70% ~~about 50%~~ sequence identity to a polypeptide having a sequence as set forth in SEQ ID NO:4 and having α -galactosidase activity.

Claim 94 (previously presented): The isolated or recombinant polypeptide of claim 93, wherein the sequence identity is determined by analysis with a sequence comparison algorithm.

Claim 95 (currently amended): The isolated or recombinant polypeptide of claim 93 having at least 99% ~~about 55%~~ sequence identity to a polypeptide having a sequence as set forth in SEQ ID NO:4.

Claims 96 to 98 (canceled)

Claim 99 (currently amended): The isolated or recombinant polypeptide of claim 93, wherein the polypeptide has ~~98 having~~ at least ~~[[about]]~~ 75% sequence identity to a polypeptide having a sequence as set forth in SEQ ID NO:4 ~~as determined by analysis with a sequence comparison algorithm or FASTA version 3.0t78 with the default parameters and~~ having α -galactosidase activity.

Claim 100 (currently amended): The isolated or recombinant polypeptide of claim 99, wherein the polypeptide has ~~[[having]]~~ at least ~~[[about]]~~ 80% sequence identity to a

sd-200174

Applicant : Murphy, et al.
Serial No. : 09/886,400
Filed : June 20, 2001
Page : 3 of 15

Attorney's Docket No.: 56446-20003.20/-004005/
D1120-4

polypeptide having a sequence as set forth in SEQ ID NO:4 as determined by analysis with a sequence comparison algorithm or FASTA version 3.0t78 with the default parameters and having α -galactosidase activity.

Claim 101 (currently amended): The isolated or recombinant polypeptide of claim 100, wherein the polypeptide has [[having]] at least [[about]] 85% sequence identity to a polypeptide having a sequence as set forth in SEQ ID NO:4 as determined by analysis with a sequence comparison algorithm or FASTA version 3.0t78 with the default parameters and having α -galactosidase activity.

Claim 102 (currently amended): The isolated or recombinant polypeptide of claim 101, wherein the polypeptide has [[having]] at least [[about]] 90% sequence identity to a polypeptide having a sequence as set forth in SEQ ID NO:4 as determined by analysis with a sequence comparison algorithm or FASTA version 3.0t78 with the default parameters and having α -galactosidase activity.

Claim 103 (currently amended): The isolated or recombinant polypeptide of claim 102, wherein the polypeptide has [[having]] at least [[about]] 95% sequence identity to a polypeptide having a sequence as set forth in SEQ ID NO:4 as determined by analysis with a sequence comparison algorithm or FASTA version 3.0t78 with the default parameters and having α -galactosidase activity.

Claim 104 (previously presented): An isolated or recombinant polypeptide having a sequence as set forth in SEQ ID NO:4.

Claim 105 (currently amended): An isolated or recombinant polypeptide having α -galactosidase activity comprising at least 10 consecutive amino acids of the polypeptide as set forth in ~~of claim 93 or~~ claim 104 and having α -galactosidase activity.

sd-200174

Applicant : Murphy, et al.
Serial No. : 09/886,400
Filed : June 20, 2001
Page : 4 of 15

Attorney's Docket No.: 56446-20003.20/-004005/
D1120-4

Claim 106 (currently amended): The isolated or recombinant polypeptide of claim 105 comprising at least 15 consecutive amino acids of the polypeptide having a sequence as set forth in SEQ ID NO:4.

Claim 107 (currently amended): The isolated or recombinant polypeptide of claim 106 comprising at least 20 consecutive amino acids of the polypeptide having a sequence as set forth in SEQ ID NO:4.

Claim 108 (currently amended): The isolated or recombinant polypeptide of claim 107 comprising at least 25 consecutive amino acids of the polypeptide having a sequence as set forth in SEQ ID NO:4.

Claim 109 (currently amended): The isolated or recombinant polypeptide of claim 108 comprising at least 30 consecutive amino acids of the polypeptide having a sequence as set forth in SEQ ID NO:4.

Claim 110 (currently amended): The isolated or recombinant polypeptide of claim 109 comprising at least 35 consecutive amino acids of the polypeptide having a sequence as set forth in SEQ ID NO:4.

Claim 111 (currently amended): The isolated or recombinant polypeptide of claim 110 comprising at least 40 consecutive amino acids of the polypeptide of claim 104.

Claim 112 (previously presented): The isolated or recombinant polypeptide of claim 111 comprising at least 50 consecutive amino acids of the polypeptide having a sequence as set forth in SEQ ID NO:4.

Claim 113 (currently amended): The isolated or recombinant polypeptide of claim 112 comprising at least 55 consecutive amino acids of the polypeptide having a sequence as set forth in SEQ ID NO:4.

sd-200174

Applicant : Murphy, et al.
Serial No. : 09/886,400
Filed : June 20, 2001
Page : 5 of 15

Attorney's Docket No.: 56446-20003.20/-004005/
D1120-4

Claim 114 (currently amended): The isolated or recombinant polypeptide of claim 113 comprising at least 100 consecutive amino acids of the polypeptide having a sequence as set forth in SEQ ID NO:4.

Claim 115 (currently amended): The isolated or recombinant polypeptide of claim 114 comprising at least 150 consecutive amino acids of the polypeptide having a sequence as set forth in SEQ ID NO:4.

Claim 116 (currently amended): An isolated or recombinant polypeptide encoded by a polynucleotide sequence having at least 70% about 50% sequence identity to SEQ ID NO:3, wherein the polypeptide has α -galactosidase activity.

Claim 117 (currently amended): An isolated or recombinant polypeptide encoded by a polynucleotide sequence having at least 70% about 50% sequence identity to SEQ ID NO:3, wherein the polypeptide catalyzes the enzymatic hydrolysis of saccharides.

Claim 118 (currently amended): An enzyme preparation comprising the polypeptide of claim 93 ~~or claim 105~~ and a liquid, wherein the polypeptide has α -galactosidase activity.

Claim 119 (currently amended): A dry enzyme preparation comprising the polypeptide of claim 93 ~~or claim 105~~, wherein the polypeptide has α -galactosidase activity.

Claim 120 (previously presented): The isolated or recombinant polypeptide of claim 116, wherein the α -galactosidase activity comprises the ability to renature and regain activity after exposure to temperatures of about 60°C to about 105°C.

Applicant : Murphy, et al.
Serial No. : 09/886,400
Filed : June 20, 2001
Page : 6 of 15

Attorney's Docket No.: 56446-20003.20/-004005/
D1120-4

Claim 121 (currently amended): The isolated or recombinant polypeptide of claim 116, wherein the polypeptide is encoded by a polynucleotide sequence having at least 97% ~~about 55%~~ sequence identity to SEQ ID NO:3.

Claims 122 to 124 (canceled)

Claim 125 (currently amended): The isolated or recombinant polypeptide of claim 116, wherein the polypeptide is encoded by a polynucleotide sequence having at least [[about]] 75% sequence identity to SEQ ID NO:3.

Claim 126 (currently amended): The isolated or recombinant polypeptide of claim 116, wherein the polypeptide is encoded by a polynucleotide sequence having at least [[about]] 80% sequence identity to SEQ ID NO:3.

Claim 127 (currently amended): The isolated or recombinant of claim 116, wherein the polypeptide is encoded by a polynucleotide sequence having at least [[about]] 85% sequence identity to SEQ ID NO:3.

Claim 128 (currently amended): The isolated or recombinant polypeptide of claim 116, wherein the polypeptide is encoded by a polynucleotide sequence having at least [[about]] 95% sequence identity to SEQ ID NO:3.

Claim 129 (previously presented): An isolated or recombinant polypeptide having α -galactosidase activity having a sequence as set forth in SEQ ID NO:4 comprising at least one conservative amino acid substitution, wherein the conservative amino acid substitution comprises substituting one hydrophobic amino acid for another or substituting one polar amino acid for another.

sd-200174

Applicant : Murphy, et al.
Serial No. : 09/886,400
Filed : June 20, 2001
Page : 7 of 15

Attorney's Docket No.: 56446-20003.20/-004005/
D1120-4

Claim 130 (currently amended): The isolated or recombinant polypeptide of claim 129, wherein arginine is substituted for lysine, ~~[[or]]~~ glutamic acid is substituted for aspartic acid, or glutamine is substituted for asparagine.

Claim 131 (previously presented): The isolated or recombinant polypeptide of claim 93 or claim 105, wherein the polypeptide is chemically linked to ~~associated with~~ a polyethylene glycol and the polypeptide has α -galactosidase activity.

Claim 132 (currently amended): An isolated or recombinant polypeptide having α -galactosidase activity comprising an enzymatically active fragment of the polypeptide of ~~claim~~ 93 ~~or~~ claim 104.

Claims 133 to 137 (canceled)

Claim 138 (new): An isolated or recombinant polypeptide having α -galactosidase activity comprising at least 10 consecutive amino acids of a polypeptide having at least 70% sequence identity to a polypeptide having a sequence as set forth in SEQ ID NO:4 and having α -galactosidase activity.

Claim 139 (new): The isolated or recombinant polypeptide of claim 138 comprising at least 15 consecutive amino acids of the isolated or recombinant polypeptide.

Claim 140 (new): The isolated or recombinant polypeptide of claim 139 comprising at least 20 consecutive amino acids of the isolated or recombinant polypeptide.

Claim 141 (new): The isolated or recombinant polypeptide of claim 140 comprising at least 25 consecutive amino acids of the isolated or recombinant polypeptide.

Claim 142 (new): The isolated or recombinant polypeptide of claim 141 comprising at least 30 consecutive amino acids of the isolated or recombinant polypeptide.

sd-200174

Applicant : Murphy, et al.
Serial No. : 09/886,400
Filed : June 20, 2001
Page : 8 of 15

Attorney's Docket No.: 56446-20003.20/-004005/
D1120-4

Claim 143 (new): The isolated or recombinant polypeptide of claim 142 comprising at least 35 consecutive amino acids of the isolated or recombinant polypeptide.

Claim 144 (new): The isolated or recombinant polypeptide of claim 143 comprising at least 40 consecutive amino acids of the isolated or recombinant polypeptide.

Claim 145 (new): The isolated or recombinant polypeptide of claim 144 comprising at least 50 consecutive amino acids of the polypeptide.

Claim 146 (new): The isolated or recombinant polypeptide of claim 145 comprising at least 55 consecutive amino acids of the polypeptide.

Claim 147 (new): The isolated or recombinant polypeptide of claim 146 comprising at least 100 consecutive amino acids of the polypeptide.

Claim 148 (new): The isolated or recombinant polypeptide of claim 147 comprising at least 150 consecutive amino acids of the polypeptide.

Claim 149 (new): An isolated or recombinant polypeptide comprising an active fragment of the polypeptide of claim 93.

Claim 150 (new): The isolated or recombinant of claim 104, wherein the polypeptide is associated with a polyethylene glycol.

Claim 151 (new): An enzyme preparation comprising the polypeptide of claim 104 and a liquid.

Claim 152 (new): A dry enzyme preparation comprising the polypeptide of claim 104.

sd-200174